Form 4: Ionis Pharmaceuticals Director Michael R. Hayden Buys $15,000 in Company Stock

Director Michael R. Hayden of Ionis Pharmaceuticals recently purchased 15,000 shares of IONS stock at an average price of $31.86.

Summary

• On May 1, 2025, Michael R. Hayden, a director of Ionis Pharmaceuticals, acquired 15,000 shares of common stock.
• The purchase was made at a weighted average price of $31.86 per share.
• Following the transaction, Hayden directly owns 50,219 shares of Ionis Pharmaceuticals common stock.
• Additionally, 2,000 shares are indirectly owned through his spouse's holdings in Genworks 2 Consulting, Inc.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock purchase by a director. While insider buying can be seen as a positive signal, it's a relatively small transaction and doesn't necessarily indicate a major shift in the company's outlook.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The stock purchase by a director could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Michael R. Hayden, stock purchase, Form 4, director, beneficial ownership, Genworks 2 Consulting